{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T16:40:50Z","timestamp":1777912850073,"version":"3.51.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:00:00Z","timestamp":1723593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:00:00Z","timestamp":1723593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s10147-024-02606-z","type":"journal-article","created":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T20:24:56Z","timestamp":1723667096000},"page":"1730-1739","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Changes in outcome of patients with advanced non-clear cell renal cell carcinoma from the tyrosine kinase inhibitor era to the immuno-oncology era"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5146-656X","authenticated-orcid":false,"given":"Hiroki","family":"Ishihara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Nemoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinsuke","family":"Mizoguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironori","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiko","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Shimmura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasunobu","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junpei","family":"Iizuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsunenori","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,14]]},"reference":[{"key":"2606_CR1","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer RJ, Tannir NM, McDermott DF et al (2018) Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 378:1277\u20131290","journal-title":"N Engl J Med"},{"key":"2606_CR2","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"Rini BI, Plimack ER, Stus V et al (2019) Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 380:1116\u20131127","journal-title":"N Engl J Med"},{"key":"2606_CR3","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","volume":"380","author":"RJ Motzer","year":"2019","unstructured":"Motzer RJ, Penkov K, Haanen J et al (2019) Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 380:1103\u20131115","journal-title":"N Engl J Med"},{"key":"2606_CR4","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa2026982","volume":"384","author":"TK Choueiri","year":"2021","unstructured":"Choueiri TK, Powles T, Burotto M et al (2021) Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 384:829\u2013841","journal-title":"N Engl J Med"},{"key":"2606_CR5","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","volume":"384","author":"R Motzer","year":"2021","unstructured":"Motzer R, Alekseev B, Rha SY et al (2021) Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med 384:1289\u20131300","journal-title":"N Engl J Med"},{"key":"2606_CR6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.6004\/jnccn.2022.0001","volume":"20","author":"RJ Motzer","year":"2022","unstructured":"Motzer RJ, Jonasch E, Agarwal N et al (2022) Kidney cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 20:71\u201390","journal-title":"J Natl Compr Canc Netw"},{"key":"2606_CR7","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.1200\/JCO.22.00868","volume":"40","author":"WK Rathmell","year":"2022","unstructured":"Rathmell WK, Rumble RB, Van Veldhuizen PJ et al (2022) Management of metastatic clear cell renal cell carcinoma: ASCO guideline. J Clin Oncol 40:2957\u20132995","journal-title":"J Clin Oncol"},{"key":"2606_CR8","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.eururo.2022.03.006","volume":"82","author":"B Ljungberg","year":"2022","unstructured":"Ljungberg B, Albiges L, Abu-Ghanem Y et al (2022) European association of urology guidelines on renal cell carcinoma: the 2022 update. Eur Urol 82:399\u2013410","journal-title":"Eur Urol"},{"key":"2606_CR9","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.euros.2022.12.015","volume":"49","author":"NJ Shah","year":"2023","unstructured":"Shah NJ, Sura SD, Shinde R et al (2023) Real-world treatment patterns and clinical outcomes for metastatic renal cell carcinoma in the current treatment era. Eur Urol Open Sci 49:110\u2013118","journal-title":"Eur Urol Open Sci"},{"key":"2606_CR10","doi-asserted-by":"publisher","first-page":"17009","DOI":"10.1038\/nrdp.2017.9","volume":"3","author":"JJ Hsieh","year":"2017","unstructured":"Hsieh JJ, Purdue MP, Signoretti S et al (2017) Renal cell carcinoma. Nat Rev Dis Primers 3:17009","journal-title":"Nat Rev Dis Primers"},{"key":"2606_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102377","volume":"106","author":"P Lombardi","year":"2022","unstructured":"Lombardi P, Filetti M, Falcone R et al (2022) New first-line immunotherapy-based combinations for metastatic renal cell carcinoma: a systematic review and network meta-analysis. Cancer Treat Rev 106:102377","journal-title":"Cancer Treat Rev"},{"key":"2606_CR12","doi-asserted-by":"publisher","first-page":"3249","DOI":"10.1007\/s00432-022-04173-0","volume":"149","author":"V St\u00fchler","year":"2023","unstructured":"St\u00fchler V, Herrmann L, Rausch S et al (2023) Real world data on IO-based therapy for metastatic renal cell carcinoma. J Cancer Res Clin Oncol 149:3249\u20133258","journal-title":"J Cancer Res Clin Oncol"},{"key":"2606_CR13","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s11523-022-00879-w","volume":"17","author":"H Ishihara","year":"2022","unstructured":"Ishihara H, Nemoto Y, Nakamura K et al (2022) Changes in real-world outcomes in patients with metastatic renal cell carcinoma from the molecular-targeted therapy era to the immune checkpoint inhibitor era. Target Oncol 17:307\u2013319","journal-title":"Target Oncol"},{"key":"2606_CR14","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s11523-023-01013-0","volume":"18","author":"A Poprach","year":"2023","unstructured":"Poprach A, Kiss I, Stanik M et al (2023) Impact of immunotherapy on real-world survival outcomes in metastatic renal cell carcinoma. Target Oncol 18:893\u2013903","journal-title":"Target Oncol"},{"key":"2606_CR15","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1200\/JCO.20.02365","volume":"39","author":"DF McDermott","year":"2021","unstructured":"McDermott DF, Lee JL, Ziobro M et al (2021) Open-label, single-arm, phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced non-clear cell renal cell carcinoma. J Clin Oncol 39:1029\u20131039","journal-title":"J Clin Oncol"},{"key":"2606_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003844","volume":"10","author":"SS Tykodi","year":"2022","unstructured":"Tykodi SS, Gordan LN, Alter RS et al (2022) Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b\/4 CheckMate 920 trial. J Immunother Cancer 10:e003844","journal-title":"J Immunother Cancer"},{"key":"2606_CR17","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.21.01944","volume":"40","author":"CH Lee","year":"2022","unstructured":"Lee CH, Voss MH, Carlo MI et al (2022) Phase II trial of cabozantinib plus nivolumab in patients with non-clear-cell renal cell carcinoma and genomic correlates. J Clin Oncol 40:2333\u20132341","journal-title":"J Clin Oncol"},{"key":"2606_CR18","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/S1470-2045(23)00276-0","volume":"24","author":"L Albiges","year":"2023","unstructured":"Albiges L, Gurney H, Atduev V et al (2023) Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial. Lancet Oncol 24:881\u2013891","journal-title":"Lancet Oncol"},{"key":"2606_CR19","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ejca.2021.04.004","volume":"151","author":"CL Gan","year":"2021","unstructured":"Gan CL, Stukalin I, Meyers DE et al (2021) Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials. Eur J Cancer 151:115\u2013125","journal-title":"Eur J Cancer"},{"key":"2606_CR20","doi-asserted-by":"publisher","first-page":"950","DOI":"10.3109\/0284186X.2013.777158","volume":"52","author":"L Mol","year":"2013","unstructured":"Mol L, Koopman M, van Gils CW et al (2013) Comparison of treatment outcome in metastatic colorectal cancer patients included in a clinical trial versus daily practice in The Netherlands. Acta Oncol 52:950\u2013955","journal-title":"Acta Oncol"},{"key":"2606_CR21","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s11523-023-00956-8","volume":"18","author":"H Ishihara","year":"2023","unstructured":"Ishihara H, Nemoto Y, Nakamura K et al (2023) Comparison of outcomes between therapeutic combinations based on immune checkpoint inhibitors or tyrosine kinase inhibitor monotherapy for first-line therapy of patients with advanced renal cell carcinoma outside of clinical trials: a real-world retrospective multi-institutional study. Target Oncol 18:209\u2013220","journal-title":"Target Oncol"},{"key":"2606_CR22","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1007\/s00277-018-3449-8","volume":"97","author":"W Knauf","year":"2018","unstructured":"Knauf W, Aldaoud A, Hutzschenreuter U et al (2018) Survival of non-transplant patients with multiple myeloma in routine care differs from that in clinical trials-data from the prospective German Tumour Registry Lymphatic Neoplasms. Ann Hematol 97:2437\u20132445","journal-title":"Ann Hematol"},{"key":"2606_CR23","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1111\/iju.14523","volume":"28","author":"H Ishihara","year":"2021","unstructured":"Ishihara H, Tachibana H, Takagi T et al (2021) Effect of improved systemic therapy on patient survival in metastatic non-clear-cell renal cell carcinoma. Int J Urol 28:605\u2013607","journal-title":"Int J Urol"},{"key":"2606_CR24","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247","journal-title":"Eur J Cancer"},{"key":"2606_CR25","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.urolonc.2021.04.013","volume":"39","author":"N Mendhiratta","year":"2021","unstructured":"Mendhiratta N, Muraki P, Sisk AE Jr et al (2021) Papillary renal cell carcinoma: review. Urol Oncol 39:327\u2013337","journal-title":"Urol Oncol"},{"key":"2606_CR26","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.eururo.2016.11.020","volume":"71","author":"S Fernandez-Pello","year":"2017","unstructured":"Fernandez-Pello S, Hofmann F, Tahbaz R et al (2017) A systematic review and meta-analysis comparing the effectiveness and adverse effects of different systemic treatments for non-clear cell renal cell carcinoma. Eur Urol 71:426\u2013436","journal-title":"Eur Urol"},{"key":"2606_CR27","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/S1470-2045(15)00515-X","volume":"17","author":"AJ Armstrong","year":"2016","unstructured":"Armstrong AJ, Halabi S, Eisen T et al (2016) Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lancet Oncol 17:378\u2013388","journal-title":"Lancet Oncol"},{"key":"2606_CR28","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.eururo.2015.10.049","volume":"69","author":"NM Tannir","year":"2016","unstructured":"Tannir NM, Jonasch E, Albiges L et al (2016) Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (ESPN): a randomized multicenter phase 2 trial. Eur Urol 69:866\u2013874","journal-title":"Eur Urol"},{"key":"2606_CR29","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1002\/cncr.28151","volume":"119","author":"N Kroeger","year":"2013","unstructured":"Kroeger N, Xie W, Lee JL et al (2013) Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria. Cancer 119:2999\u20133006","journal-title":"Cancer"},{"key":"2606_CR30","doi-asserted-by":"publisher","first-page":"294.e291","DOI":"10.1016\/j.urolonc.2018.12.017","volume":"37","author":"A Poprach","year":"2019","unstructured":"Poprach A, Rumanova K, Lakom\u00fd R et al (2019) Tyrosine kinase inhibitors in the first-line treatment for metastatic nonclear cell renal carcinoma: a retrospective analysis of a national database. Urol Oncol 37:294.e291-294.e298","journal-title":"Urol Oncol"},{"key":"2606_CR31","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.clgc.2017.03.004","volume":"15","author":"G de Velasco","year":"2017","unstructured":"de Velasco G, McKay RR, Lin X et al (2017) Comprehensive analysis of survival outcomes in non-clear cell renal cell carcinoma patients treated in clinical trials. Clin Genitourin Cancer 15:652-660.e651","journal-title":"Clin Genitourin Cancer"},{"key":"2606_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102228","volume":"99","author":"M de Vries-Brilland","year":"2021","unstructured":"de Vries-Brilland M, McDermott DF, Su\u00e1rez C et al (2021) Checkpoint inhibitors in metastatic papillary renal cell carcinoma. Cancer Treat Rev 99:102228","journal-title":"Cancer Treat Rev"},{"key":"2606_CR33","doi-asserted-by":"crossref","unstructured":"Massari F, Mollica V, Fiala O et al (2024) Papillary renal cell carcinoma: outcomes for patients receiving first-line immune-based combinations or tyrosine kinase inhibitors from the ARON-1 study. Eur Urol Oncol","DOI":"10.1016\/S0302-2838(24)01410-6"},{"key":"2606_CR34","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1111\/iju.15128","volume":"30","author":"K Izumi","year":"2023","unstructured":"Izumi K, Inoue M, Washino S et al (2023) Clinical outcomes of nivolumab plus ipilimumab in patients with metastatic non-clear cell renal cell carcinoma: real-world data from a Japanese multicenter retrospective study. Int J Urol 30:714\u2013721","journal-title":"Int J Urol"},{"key":"2606_CR35","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1200\/JCO.22.02600","volume":"41","author":"JT Brown","year":"2023","unstructured":"Brown JT, Nazha B, Bilen MA (2023) Combined programmed death-ligand 1 and MET inhibition: has papillary renal cell carcinoma met its match? J Clin Oncol 41:2467\u20132470","journal-title":"J Clin Oncol"},{"key":"2606_CR36","doi-asserted-by":"publisher","first-page":"3411","DOI":"10.1158\/1078-0432.CCR-13-2173","volume":"20","author":"L Albiges","year":"2014","unstructured":"Albiges L, Guegan J, Le Formal A et al (2014) MET is a potential target across all papillary renal cell carcinomas: result from a large molecular study of pRCC with CGH array and matching gene expression array. Clin Cancer Res 20:3411\u20133421","journal-title":"Clin Cancer Res"},{"key":"2606_CR37","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41581-020-0301-x","volume":"16","author":"N Dizman","year":"2020","unstructured":"Dizman N, Philip EJ, Pal SK (2020) Genomic profiling in renal cell carcinoma. Nat Rev Nephrol 16:435\u2013451","journal-title":"Nat Rev Nephrol"},{"key":"2606_CR38","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1016\/j.celrep.2016.02.024","volume":"14","author":"F Chen","year":"2016","unstructured":"Chen F, Zhang Y, Senbabaoglu Y et al (2016) Multilevel genomics-based taxonomy of renal cell carcinoma. Cell Rep 14:2476\u20132489","journal-title":"Cell Rep"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02606-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-024-02606-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02606-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T01:01:55Z","timestamp":1729904515000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-024-02606-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,14]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["2606"],"URL":"https:\/\/doi.org\/10.1007\/s10147-024-02606-z","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,14]]},"assertion":[{"value":"18 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Toshio Takagi received honoraria from Bristol-Myers Squibb and Ono Pharmaceutical. Tsunenori Kondo received honoraria from Pfizer, Novartis, Bristol-Myers Squibb, and Ono Pharmaceutical. No other disclosures were reported.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}